| Literature DB >> 36146692 |
André Luiz N Parcial1, Natália Gedeão Salomão1, Elyzabeth Avvad Portari2, Laíza Vianna Arruda1, Jorge José de Carvalho3, Herbert Leonel de Matos Guedes1, Thayana Camara Conde4, Maria Elizabeth Moreira2, Marcelo Meuser Batista2, Marciano Viana Paes1, Kíssila Rabelo3, Adriano Gomes-Silva1,5.
Abstract
SARS-CoV-2 is a virus that belongs to the Betacoronavirus genus of the Coronaviridae family. Other coronaviruses, such as SARS-CoV and MERS-CoV, were associated with complications in pregnant women. Therefore, this study aimed to report the clinical history of five pregnant women infected with SARS-CoV-2 (four symptomatic and one asymptomatic who gave birth to a stillborn child) during the COVID-19 pandemic. They gave birth between August 2020 to January 2021, a period in which there was still no vaccination for COVID-19 in Brazil. In addition, their placental alterations were later investigated, focusing on macroscopic, histopathological, and ultrastructural aspects compared to a prepandemic sample. Three of five placentas presented SARS-CoV-2 RNA detected by RT-PCRq at least two to twenty weeks after primary pregnancy infection symptoms, and SARS-CoV-2 spike protein was detected in all placentas by immunoperoxidase assay. The macroscopic evaluation of the placentas presented congested vascular trunks, massive deposition of fibrin, areas of infarctions, and calcifications. Histopathological analysis showed fibrin deposition, inflammatory infiltrate, necrosis, and blood vessel thrombosis. Ultrastructural aspects of the infected placentas showed a similar pattern of alterations between the samples, with predominant characteristics of apoptosis and detection of virus-like particles. These findings contribute to a better understanding of the consequences of SARS-CoV-2 infection in placental tissue, vertical transmission.Entities:
Keywords: COVID-19; inflammation; pathogenesis; pregnant women; viral particles
Mesh:
Substances:
Year: 2022 PMID: 36146692 PMCID: PMC9500736 DOI: 10.3390/v14091885
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.818
Clinical and demographic description of the five cases. * This case was considered for analysis because, although asymptomatic, the baby was stillborn during the high pandemic outbreak period and subsequently confirmed the SARS-CoV-2 detection by immunohistochemistry.
| Case 1 | Case 2 | Case 3 * | Case 4 | Case 5 | |
|---|---|---|---|---|---|
|
| 37 | 38 | 39 | 28 | 27 |
|
|
Fever Headache Dry cough Nasal congestion Runny nose Myalgia Fatigue Nasal bleeding |
Fever Cough | Not presented symptoms |
Chills Headache Dry cough Nasal congestion Rhinorrhea Myalgia Arthralgia Fatigue Vomiting Nausea |
Fever Chills headache Dry cough Sore throat Sneezing Nasal congestion Rhinorrhea Anosmia Loss of taste Chest pain Shortness of breath Myalgia Arthralgia Fatigue Abdominal pain Diarrhea |
|
| 19 weeks | 38 weeks | - | 39 weeks | 35 weeks |
|
| 39 weeks and 4 days | 38 weeks | 39 weeks | 41 weeks and 1 day | 37 weeks and 4 days |
|
| Nasopharyngeal PCR was not performed. | No nasopharyngeal PCR or serology was performed | Negative nasopharyngeal PCR | IgG and IgA in the day of delivery | IgG in the day of delivery |
|
| No | No | Asthma | Obesity and hypothyroidism | Asthma |
|
| Apgar 9/10 | Fetal death | - | Apgar 9/10, presence of anti-SARS-CoV-2 IgG antibodies | Apgar 7/8 |
|
| Positive | Positive | Not performed | Not performed | Positive |
Figure 1Macroscopic evaluation of placentas. (A–C) Prepandemic COVID-19 control fresh placenta; (A) fetal face; (B) maternal face; (C) cleaved placenta; (D–H) SARS-CoV-2-infected placentas; (D–F) cleaved and fixed placenta of the second case; (G) fresh fetal face of the third case; (H) fresh maternal face of the third case. These are photographs of representative placenta from participants who had pregnancies during the COVID-19 pandemic.
Figure 2Histopathological changes in SARS-CoV-2-infected placentas. (A) Prepandemic control placenta with regular aspect. (B–F) Representative microphotographs of SARS-CoV-2-infected placentas. Fibrin deposition (Fi); trophoblastic necrosis (red arrow); villitis (Vi); chronic villitis (Vi); avascular villi (green arrow); decidual vessel thrombosis (Tv); and intervillitis (Iv).
Figure 3Detection of spike protein in placental cells. (A) Pre-pandemic control placenta. (B–M) Spike protein detected in: (B–D) Representative microphotographs of SARS-CoV-2 infected placentas. HBC—Hofbauer cells; FC—circulating cells of fetal capillary; yellow arrows—trophoblastic cells; MC—macrophages.
Figure 4Ultrastructural changes in SARS-CoV-2 infected placental cells and presence of viral particles. (A–C) Prepandemic control placental sample with normal-looking syncytiotrophoblast (STB) and cytotrophoblast (CTB) cells. (D–O) Samples from infected placentas, with altered morphology. (E) Higher magnification of the viral cluster area. (N) nucleus; (M) mitochondria; (ER) endoplasmic reticulum; (V) villi; (AB) apoptotic bodies. Arrowheads indicate viral particles of approximately 70 nm, compatible with the size of SARS-CoV-2.